Bullish Amarin doubling sales force in fast run-up to the big FDA decision on Vascepa
Amarin is hiring. And that will likely get the buzz about this biotech’s near-term future back in play.
In a statement out early Tuesday, Amarin execs said they plan to go ahead and get started doubling the sales force, recruiting hundreds of new staffers as they gear up for the much-anticipated re-launch of Vascepa with a blockbuster label rewrite hanging at the FDA.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 59,600+ biopharma pros reading Endpoints daily — and it's free.